• Explore /
  • Poster
  • / Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PI3KCA</i> wild type (4WT). GEMCAD 1601 PIER trial.

Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial.

Abstract Poster

Authors

null

Carlos Fernandez-Martos

Hospital Quironsalud, Valencia, Spain

Carlos Fernandez-Martos , Carles Pericay , Joan Maurel , Ana Virgili , Jaume Capdevila , Javier Gallego , Ruth Vera , Nuria Rodriguez-Salas , Ferran Losa , Manuel Valladares , Ana Vivancos , Juan Ayuso , Monique Maas , Fernando Martínez , Marcos Melian , Xabier García de Albéniz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Other Colorectal and Anal Cancer

Clinical Trial Registration Number

NCT03000374

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3512)

DOI

10.1200/JCO.2021.39.15_suppl.3512

Abstract #

3512

Abstract Disclosures

Similar Posters

First Author: Carlos Fernandez-Martos

First Author: Kimberly Perez

First Author: Carlos Fernandez-Martos

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.

Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.

First Author: Janice Zhao